- Home
- HSAI vs AUPH Comparison
HSAI vs AUPH Comparison
Compare HSAI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSAI | AUPH |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HSAI | AUPH |
|---|---|---|
| Price | $16.52 | $16.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $31.58 | $17.25 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $46.29 | $17.54 |
| Revenue Next Year | $41.32 | $15.74 |
| P/E Ratio | ★ $61.18 | $64.92 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $14.40 | $8.55 |
| 52 Week High | $30.85 | $19.25 |
Technical Indicators
Market Signals| Indicator | HSAI | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 52.47 |
| Support Level | $14.55 | $14.37 |
| Resistance Level | $24.30 | $19.25 |
| Average True Range (ATR) | 0.89 | 0.90 |
| MACD | 0.17 | -0.11 |
| Stochastic Oscillator | 46.04 | 33.62 |
Price Performance
Historical ComparisonAbout HSAI Hesai Group each ADS represents one Class B ordinary share
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.